Market Intelligence, Clinical Progress, and High-Purity Reagents for FGFR3-Driven Oncology and Achondroplasia Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for FGFR3 drug discovery. The table below outlines available components for wild-type and mutant FGFR3 proteins, gene delivery, benchmark antibodies, validation tools, and cross-reactivity panels for subfamily selectivity screening.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Wild-Type) | FGFR3 ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). Theoretical MW: 65-75 kDa. |
View FGFR3 Products |
| Antigen (Mutant Panel) | FGFR3 S249C, R248C, Y373C, K650E Mutant Proteins Clinical mutation variants for resistance/activation profiling. Sequence Verified. |
View FGFR3 Products |
| Gene Delivery | FGFR3 Promise-ORF / Lentivirus Premade Particles Full-length ORF with native signal peptide. For stable cell line construction. CMV promoter. |
View FGFR3 Products |
| Benchmark Ab | Anti-FGFR3 Antibody (Recombinant, Sequence of Vofatamab) Positive control for binding/blocking assays. Human IgG1 format, sequences available. |
View FGFR3 Products |
| Validator | FGFR3 siRNA Set (3 target-specific + 1 control) For knockdown verification and specificity confirmation. HPLC purified. |
View FGFR3 Products |
| Cross-Reactivity Panel | FGFR1 ECD-Fc Protein Close homolog (61% identity in kinase domain) for selectivity screening. |
View FGFR1 Products |
| Cross-Reactivity Panel | FGFR2 ECD-Fc Protein Paralog for counter-screening. High purity, HEK293 expressed. |
View FGFR2 Products |
| Cross-Reactivity Panel | FGFR4 ECD-Fc Protein Off-target safety liability control for pan-FGFR inhibitors. |
View FGFR4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species Cyno/Mouse Eval | Human/Mouse/Cyno ortholog FGFR3 ECD proteins available with >95% purity; Sequence identity verified by Mass Spec |
| Subfamily Selectivity (FGFR1/2/4) | Homolog panel proteins (FGFR1, FGFR2, FGFR4) strictly sequence-verified; Theoretical MW confirmed |
| Mutant vs Wild-Type Discrimination | FGFR3 S249C, R248C, Y373C mutant proteins available; Sequence verified against ClinVar entries |
| ADC Internalization Assays | High-purity ECD-Fc with native conformation for ligand-competition studies; Endotoxin controlled |
| Lack of Positive Controls | Clinical Benchmark Antibodies (recombinant format, sequence-matched to vofatamab) included for assay validation |
| False Positives in Binding | Validated FGFR3 siRNA included for specificity checks; Lentivirus for stable knockdown cell lines |
| Drug Resistance Mutations | Mutant recombinant proteins (S249C, R248C, K650E) available; native glycosylation from HEK293 for conformational relevance |
Live FGFR3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The FGFR3 therapeutic landscape has shifted from pan-FGFR inhibition (Erdafitinib, Pemigatinib, Infigratinib) toward selective FGFR3 targeting and Antibody-Drug Conjugates (ADCs) to minimize FGFR1/4-mediated toxicities (hyperphosphatemia, tissue calcification, hepatotoxicity). As first-generation inhibitors face resistance via kinase domain gatekeeper mutations (V555M, L608F) and activating mutations in the extracellular domain (S249C, Y373C, R248C), the next wave of R&D is targeting allosteric sites, mutant-selective inhibitors, and novel modalities like bispecific antibodies and PROTACs. Simultaneously, bladder cancer and multiple myeloma programs are increasingly requiring patient stratification assays based on specific FGFR3 mutations rather than amplification status alone. In the non-oncology space, monoclonal antibodies (e.g., Therachon/Pfizer) are being developed for achondroplasia, creating additional assay needs for receptor-blocking studies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Pan-FGFR Inhibitor (Small Molecule) | Janssen, Incyte, QED Therapeutics | Urothelial Carcinoma, Cholangiocarcinoma | Subfamily Selectivity Assay (Need FGFR1/2/4 counter-screening proteins) |
| Selective FGFR3 Inhibitor | Eli Lilly, Relay Therapeutics, Tyra Biosciences | Solid Tumors (FGFR3-mutant) | Mutant vs WT Discrimination (Need S249C, Y373C, K650E mutant proteins) |
| ADC | Seagen/Pfizer, AstraZeneca, Daiichi Sankyo | Bladder Cancer, NSCLC, Solid Tumors | Internalization Assay (Need high-purity ECD-Fc for ligand blocking studies) |
| Monoclonal Antibody | Therachon / Pfizer, Rainier Therapeutics | Achondroplasia, Solid Tumors | Receptor Blocking & Cross-species Binding (Need Human/Cyno/Mouse orthologs) |
| Bispecific Ab / PROTAC | Genentech, ABL Bio, Emerging Biotechs | Solid Tumors | Heterodimer / Ternary Complex Validation (Need Cross-reactive Abs and isoform-specific reagents) |
Target Identity & Key Mutations
FGFR3 (CD333) is a receptor tyrosine kinase with three Ig-like C2-type domains (Ig-like C2-type 1, 2, 3) in the extracellular region. Clinically relevant mutations include the extracellular domain mutations S249C, R248C, Y373C (common in bladder cancer) and the kinase domain mutation K650E (lethal skeletal dysplasia). Somatic mutations have been observed in lung adenocarcinoma and colorectal adenocarcinoma samples (dbSNP:rs2305178). These variants drive ligand-independent dimerization or constitutive kinase activation, making mutant-selective reagents critical for drug development.
Related Targets for Cross-Sell
- FGFR1 (CD331): Most significant off-target toxicity source; selectivity screening essential for any FGFR3 program. Also a driver in lung cancer.
- FGFR2 (CD332): Highest homology to FGFR3; gold-standard negative control for selectivity. FGFR2 fusions are key in cholangiocarcinoma.
- FGFR4 (CD334): Mediates liver toxicity; counter-screening recommended to exclude hepatotoxic compounds.
- PD-L1 (CD274): FGFR3 inhibitors are increasingly combined with immune checkpoint inhibitors (e.g., Erdafitinib + Cetrelimab in urothelial carcinoma), offering additional assay needs for combination studies.